F Jafari; Sh Moradi; MA Nilforoush Zadeh; R Derakhshan; N Ansari
Volume 9, Issue 3 , 2006, , Pages 211-216
Abstract
Background and aim: Cutaneous leishmaniasis is an endemic disease in Iran. Although there are many different treatments for this disease, there is not any effective treatment yet. Since there has been a number of different reports on the effectiveness of Cassia fistula plant in the treatment of leishmaniasis, ...
Read More
Background and aim: Cutaneous leishmaniasis is an endemic disease in Iran. Although there are many different treatments for this disease, there is not any effective treatment yet. Since there has been a number of different reports on the effectiveness of Cassia fistula plant in the treatment of leishmaniasis, the efficacy of concentrated boiled extract and hydro alcoholic extract of Cassia fistula on the leishmaniasis disease was compared with intralesional injection of Glucantime in this study.Materials and Methods: In this randomized clinical trial a total of 165 patients, 6 to 60 years old, who had a positive leishmania smear refered to the Isfahan Skin and Leishmaniasis Research Center were divided into three groups using list of random numbers and were treated with: concentrated boiled extract of Cassia fistula, hydroalcholic extract of Cassia fistula, or intralesional injection of Glucantime. The patients were treated for 4 weeks and followed for three months after the study started. The efficacy of treatment was reported as complete cure, partial improvement and no improvement on the basis of clinical and parasitological evidence.Results: In the present study 63/6% of patients treated with the concentrated boiled extract, 52/7% of the hydroalcoholic extract and 45/5% of the Glucantime group were men. 22 patients (40%) of the concentrated boiled extract of Cassia fistula, 20 pateints (36/4%) of the hydroalcoholic extract of Cassia fistula group and 36 patients (65/5%) of the Glucantime group showed complete cure. The efficacy in the third group was much more than the first (P<0.02) and second groups (P<0.005), but there was not any difference between concentrated boiled extract and hydroalcoholic extract of Cassia fistula.Conclusion: The results of this study showed that this plant might be used topically along with Glucantime for decreasing the time and dose of treatment with Glucantime.
MA Nilforoush Zadeh; Sh Moradi; R Derakhshan; E Haft Baradaran; F Jafari
Volume 9, Issue 3 , 2006, , Pages 221-226
Abstract
Background and aim: Cutaneous leishmaniasis (CL) is an edemic disease widely spread in Iran. Although several treatments have been tried, none has been found as simple and effective. Honey has been used in the treatment of chronic ulcers and its anti-leishmanial effects have also been reported. So we ...
Read More
Background and aim: Cutaneous leishmaniasis (CL) is an edemic disease widely spread in Iran. Although several treatments have been tried, none has been found as simple and effective. Honey has been used in the treatment of chronic ulcers and its anti-leishmanial effects have also been reported. So we assessed the efficacy of honey in acute CL.Materials and Methods: In a randomized clinical trial, 100 patients with CL referred to Skin and Leishmaniasis Research Center were treated with either weekly intra-lesional injection of Glucantime alone or combined with twice daily topical application of honey. The patients were evaluated clinically 2 ,3 and 4 months after treatment.Results: Ninety patients completed the study, forty-five patients were treated in each group. At the end of trial, 32 patients (71/1%) of these treated with Glucantime alone and 23 patients (51/1%) treated with honey were cured (P=0.04).Conclusion: Drug interference and inhibition of bioavailability of Glucantime by honey may decrease the efficacy of Glucantime in treatment of CL.
MA Nilforoush Zadeh; G Sadeghian; F Jafari; AR Firooz; Sh Moradi; R Derakhshan
Volume 9, Issue 1 , 2006, , Pages 35-39
MA Nilfroush Zadeh; N Anasri; R Derakhshan
Volume 8, Issue 6 , 2006, , Pages 457-461
Abstract
Background and aim: Pentavalent antimony compounds are the first line treatment for cutaneous leishmaniasis. Clinical resistance to pentavalent antimony in the form of meglumine antimoniate (Glucantime) has been recognized as a problem in leishmaniasis. Herein, clinical response to Glucantime were studied ...
Read More
Background and aim: Pentavalent antimony compounds are the first line treatment for cutaneous leishmaniasis. Clinical resistance to pentavalent antimony in the form of meglumine antimoniate (Glucantime) has been recognized as a problem in leishmaniasis. Herein, clinical response to Glucantime were studied in patients suffered from cutaneous leishmaniasis.Materials and Methods: In a cross-sectional study 370 patients with cutaneous leishmaniasis were treated with systemic Glucantime, 50 mg/kg/day, for 2 to 3 weeks. They were visited weekly for 3 weeks and also followed up for 3 months after treatment was completed. The clinical and parasitological response to this treatment was evaluated, and classified into partial and complete response and failure to treatment. Results: Two hundred forty-seven men and 123 women were followed up. The mean age was 36.7±16 years. There were 64.1% partial response after 2 weeks and 73% partial response at the third week of treatment. 11.6% of lesions were not cured after 3 weeks of treatment and 8.1% were not still cured 12 weeks thereafter.Conclusion: Clinical resistance to Glucantime is an important problem. The mechanisms of resistance and using drug combinations are needed to be considered.